Search research articles
Contact Us
Filters
Showing results (1-10 of 24) with videos related to
Page
of 3
Sort By:
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|
November 4, 2008
A rare cause of mediastinal mass: Primary liposarcoma
N Barbetakis, G Samanidis, D Paliouras, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 23, 2011
A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer
A G Pallis, I Boukovinas, A Ardavanis, et al.
Ecancermedicalscience
|
January 26, 2012
Detection of methylation in the CpG islands of the p16INK4A, RASSF 1A and methylguanine methyltransferase gene promoters in pancreatic adenocarcinoma
D Paikos, P Stravoravdi, S Voyatzi, et al.
Oncology
|
April 29, 2006
Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan
N Ziras, A Potamianou, I Varthalitis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2015
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
D Mavroudis, E Saloustros, N Malamos, et al.
ESMO Open
|
November 13, 2021
Vaccine third dose and cancer patients: necessity or luxury?
G Pappas, E Saloustros, A Boutis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2004
Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial
J Souglakos, K Syrigos, A Potamianou, et al.
British Journal of Cancer
|
April 17, 2008
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
J Souglakos, I Boukovinas, M Taron, et al.
Breast (Edinburgh, Scotland)
|
October 5, 2013
A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer
K Tryfonidis, I Boukovinas, N Xenidis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 14, 2006
Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group
I Boukovinas, N Androulakis, L Vamvakas, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 24) with videos related to
Sort By:
Page
of 3
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|
November 4, 2008
A rare cause of mediastinal mass: Primary liposarcoma
N Barbetakis, G Samanidis, D Paliouras, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 23, 2011
A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer
A G Pallis, I Boukovinas, A Ardavanis, et al.
Ecancermedicalscience
|
January 26, 2012
Detection of methylation in the CpG islands of the p16INK4A, RASSF 1A and methylguanine methyltransferase gene promoters in pancreatic adenocarcinoma
D Paikos, P Stravoravdi, S Voyatzi, et al.
Oncology
|
April 29, 2006
Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan
N Ziras, A Potamianou, I Varthalitis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2015
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
D Mavroudis, E Saloustros, N Malamos, et al.
ESMO Open
|
November 13, 2021
Vaccine third dose and cancer patients: necessity or luxury?
G Pappas, E Saloustros, A Boutis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2004
Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial
J Souglakos, K Syrigos, A Potamianou, et al.
British Journal of Cancer
|
April 17, 2008
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
J Souglakos, I Boukovinas, M Taron, et al.
Breast (Edinburgh, Scotland)
|
October 5, 2013
A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer
K Tryfonidis, I Boukovinas, N Xenidis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 14, 2006
Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group
I Boukovinas, N Androulakis, L Vamvakas, et al.
Page
of 3